How Strong Are GlaxoSmithKline plc’s Dividends?

Dividends at GlaxoSmithKline plc (LON: GSK) might not be safe!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKlineGlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has been steadily lifting its dividend year-on-year, offering yields of around 5% — there’s 5.1% pencilled in for this year, on a share price of 1,568p.

That’s an attractive yield, especially in low-interest times and when the FTSE 100‘s average annual cash payout amounts to only around 3%.

But look back a few years, and a slightly worrying trend appears — dividend cover is falling.

Falling cover

The 61p dividend paid in 2009 was approximately twice covered by earnings per share. Leaving out the anomalous year of 2010 when major restructuring and legal cost caused bottom-line earnings to slump, by 2011 we saw a 70p dividend covered 1.6 times by earnings. And that continued, with cover dropping to 1.5 times in 2012 and to 1.4 times by 2013.

By 2013, EPS was down 7% from its 2009 figure, yet the dividend had been lifted by 28%.

And cover is set to fall further. Analysts are currently forecasting a 7% fall in EPS this year, yet the dividend looks set to be raised by another 4.5% to lower cover to under 1.3 times. We’ve already seen a 6% rise in the first-quarter dividend, although the firm did make it clear that it enjoyed free cash flow of £0.5bn.

Dividend commitment

And we were told that “GSK’s commitment is to use free cash flow to support increasing dividends, undertake share repurchases or, where returns are more attractive, reinvest in the business, including bolt-on acquisitions“.

Predictions for 2015 look a bit better, with a 10% EPS rise taking cover up a little to 1.35 times — but is that still a little low for comfort?

On top of the dividends, Glaxo is also handing out extra cash in the form of share buybacks — which take the firm’s effective annual cash returns to around the 7% level. In total, 2013’s cash handbacks amounted to £4.7bn, and there’s a further £1-2bn in buybacks planned for 2014.

A bit wary

This all looks great, especially to someone who likes strong blue-chip dividends, but I confess I’m a little concerned over the low and falling dividend cover. It’s great during good years when the cash is there, but with the cyclical nature of drug development I’d really like to see a little more breathing space between earnings and dividends — at rival AstraZenenca, despite several years of falling earnings, dividends are still set to be covered 1.5 times by 2015.

But on the other hand, ace investor Neil Woodford is a big fan GlaxoSmithKline, and he has a few shares tucked away in his market-beating portfolios.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan does not own any shares in GlaxoSmithKline or AstraZeneca. The Motley Fool has recommended shares in Glaxo.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »